NanoViricides Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.27
- Today's High:
- $1.341
- Open Price:
- $1.28
- 52W Low:
- $1.04
- 52W High:
- $2.03
- Prev. Close:
- $1.3
- Volume:
- 7490
Company Statistics
- Market Cap.:
- $15.21 million
- Book Value:
- 1.562
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -20.18%
- Return on Equity TTM:
- -31.63%
Company Profile
NanoViricides Inc had its IPO on 2005-10-26 under the ticker symbol NNVC.
The company operates in the Healthcare sector and Biotechnology industry. NanoViricides Inc has a staff strength of 17 employees.
Stock update
Shares of NanoViricides Inc opened at $1.28 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.27 - $1.34, and closed at $1.31.
This is a +0.77% increase from the previous day's closing price.
A total volume of 7,490 shares were traded at the close of the day’s session.
In the last one week, shares of NanoViricides Inc have slipped by -9.66%.
NanoViricides Inc's Key Ratios
NanoViricides Inc has a market cap of $15.21 million, indicating a price to book ratio of 0.7025 and a price to sales ratio of 0.
In the last 12-months NanoViricides Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-6313275. The EBITDA ratio measures NanoViricides Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NanoViricides Inc’s operating margin was 0% while its return on assets stood at -20.18% with a return of equity of -31.63%.
In Q1, NanoViricides Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
NanoViricides Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NanoViricides Inc’s profitability.
NanoViricides Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.3563. Its price to sales ratio in the trailing 12-months stood at 0.
NanoViricides Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $18.58 million
- Total Liabilities
- $348744.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $59301
- Dividend Payout Ratio
- 0%
NanoViricides Inc ended 2024 with $18.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.58 million while shareholder equity stood at $18.23 million.
NanoViricides Inc ended 2024 with $0 in deferred long-term liabilities, $348744.00 in other current liabilities, 11666.00 in common stock, $-127510756.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.65 million and cash and short-term investments were $9.65 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
NanoViricides Inc’s total current assets stands at $9.93 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $62695.00 and inventory worth $0.
In 2024, NanoViricides Inc's operating cash flow was $0 while its capital expenditure stood at $59301.
Comparatively, NanoViricides Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.31
- 52-Week High
- $2.03
- 52-Week Low
- $1.04
- Analyst Target Price
- $5.25
NanoViricides Inc stock is currently trading at $1.31 per share. It touched a 52-week high of $2.03 and a 52-week low of $2.03. Analysts tracking the stock have a 12-month average target price of $5.25.
Its 50-day moving average was $1.44 and 200-day moving average was $1.34 The short ratio stood at 11.27 indicating a short percent outstanding of 0%.
Around 437.9% of the company’s stock are held by insiders while 1074% are held by institutions.
Frequently Asked Questions About NanoViricides Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.